Northbrook, IL (PRWEB) July 18, 2013
NORTHBROOK, IL—July 18, 2013—Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, together with Xtalks, will host an interactive webinar entitled: “Each Hour Counts: Improving Management of Carbapenem-Resistant Enterobacteriaceae (CRE) and Other Antibiotic-Resistant Bloodstream Infections with Rapid Molecular Diagnostics.” The complimentary webinar will be held on Wednesday, August 14, 2013 at 1:00pm EDT.
To register for this event, please visit: http://xtalks.com/eachhourcounts.ashx.
Each year in the United States, there are more than 1.5 million hospital stays associated with bloodstream infections and septicemia, resulting in nearly 100,000 deaths and over $15 billion in healthcare costs .
Treatment of these serious bacterial infections in clinical practice is often complicated by antibiotic resistance, which has been associated with prolonged hospital stays, higher health care costs and increased mortality. The recent emergence of CREs is especially troubling, as there are very few antibiotic alternatives available to treat these bacteria.
In this webinar, Karen Carroll, M.D., Professor of Pathology and Medicine at Johns Hopkins University School of Medicine; Nathan Ledeboer, Ph.D., Assistant Professor of Pathology, Medical College of Wisconsin; and Debra Goff, PharmD, Clinical Associate Professor at The Ohio State University College of Pharmacy, will discuss strategies for managing antibiotic-resistant bacterial infections. These recognized leaders will review new molecular technologies that identify bacteria and corresponding antibiotic resistance more rapidly than traditional culture methods, and may enable earlier optimization of antibiotic therapy, thereby improving patient outcomes.
Registrants may qualify to receive a P.A.C.E. continuing education credit for this webinar.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for multiplexed infectious disease, genetic and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere’s product portfolio includes the Verigene Gram-Positive Blood Culture (BC-GP) (510(k) cleared; CE Mark) and Gram-Negative Blood Culture (BC-GN) (RUO; IUO; CE Mark) Tests. Nanosphere is based in Northbrook, IL.
For additional information regarding Nanosphere's infectious disease products, please contact Nanosphere at IDtesting(at)nanosphere(dot)us or visit http://www.nanosphere.us.
Roger Moody, Chief Financial Officer
Lindsey Saxon, Director of Communications
Karen Lim, Director of Member Services
+1 416-977-6555 ext 227
 Elixhauser, A. (Agency for Healthcare Research and Quality), Friedman, B. (Agency for Healthcare Research and Quality) and Stranges, E. (Thomson Reuters). Septicemia in U.S. Hospitals, 2009. HCUP Statistical Brief #122. October 2011. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf
Read the full story at http://www.prweb.com/releases/2013/7/prweb10925090.htm.
Copyright©2012 Vocus, Inc.
All rights reserved